62: A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England.
Authors
Yip, KConibear, J
Woolf, David K
Tarver, K
Willis, B
Hall, S
Sun, F
Kuhan, H
Lambourne, B
Piskilidis, P
Kussaibati, R.
Martin, L
Satar, N
Gray, C
Khan, Adeel
Doherty, G
Prewett, S
Smith, M
Dancey, G
Patterson, D
Rimmer, Y
Hollingdale, A.
Ingle, C
Tasigiannopoulos, Z
Aslam, S
Waite, K
Polychronis, A
Ghafoor, Q
Baijal, S
Newsom-Davis, T
Shah, R
Forster, M
Mulatero, C
Greystoke, A
Postmus, P
Blackhall, Fiona H
Gilligan, D
Affiliation
Oncology, Ipswich Hospital, IpswichIssue Date
2017-01
Metadata
Show full item recordCitation
62: A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England. 2017, 103(suppl 1):S28-S29 Lung CancerJournal
Lung CancerDOI
10.1016/S0169-5002(17)30112-5Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S0169500217301125Type
ArticleLanguage
enISSN
01695002ae974a485f413a2113503eed53cd6c53
10.1016/S0169-5002(17)30112-5